Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on August 05, 2026, to consider issuance of up to 70,00,000 fully convertible warrants to an entity belonging to the 'promoter & promoter group' on preferential basis.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has submitted a newspaper publication regarding the holding of an Extraordinary General Meeting (EGM) through Video Conference (VC) or Other Audio-Visual Means (OAVM) on August 05, 2026.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on July 10, 2026. The Board of Directors has transacted the following business: issue and allotment of up to 70,00,000 (Seventy Lakh) Fully Convertible Warrants to Essix Biosciences Limited on a preferential basis at an issue price of Rs. 196/- per Warrant, alteration in the Article of Association, consideration and approval of the notice convening the Extra-Ordinary General Meeting, and appointment of CS Vishal Arora as Scrutinizer.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited announced the amendment of its 'Code of Fair Disclosure, Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and Immediate Relatives of Designated Persons, and Legitimate Purpose Policy'. This update, approved by the Board of Directors on June 22, 2026, aligns the company's internal policy with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The amended code, a 31-page document, has been hosted on the company's website.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange about the resignation of a Director/Key Managerial Personnel (KMP)/Senior Management Personnel (SMP). This announcement is a routine disclosure regarding a change in the company's management structure.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has formally informed the Exchange about the resignation of a Director/Key Managerial Personnel (KMP)/Senior Management Personnel (SMP). The announcement did not provide specific details regarding the identity of the individual, their specific role, or the reasons behind their departure from the company.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has announced the resignation of Mr. Prabhat Khurana from his position as a Non-Executive Independent Director. His resignation is effective from the close of business hours on June 22, 2026, citing personal and professional commitments as the reason. Mr. Khurana confirmed that there are no other material reasons for his departure. The company's Board of Directors acknowledged and appreciated his valuable contributions during his tenure.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited announced the re-appointment of Mr. Rajinder Kumar Gupta as a Non-Executive Independent Director for a second five-year term, effective June 23, 2026, subject to shareholder approval. Mr. Gupta, a retired Additional Commissioner of Income Tax and an advocate, brings extensive experience in tax, regulatory compliance, and legal matters. The Board also reconstituted key committees, including Audit, Stakeholders Relationship, and Risk Management, where Mr. Gupta has been assigned roles, leveraging his expertise for enhanced corporate governance.